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Abstract
Objectives. While the safety of non-steroidal anti-inflammatory
drugs in COVID-19 has been questioned, they may be beneficial
given the hyper-inflammatory immune response associated with
severe disease. We aimed to assess the safety and potential efficacy
of cyclooxygenase-2 (COX-2) selective inhibitors in high-risk
patients. Methods. Retrospective study of patients with COVID-19
pneumonia and aged ≥ 50 years who were admitted to hospital.
Adverse outcomes analysed included supplemental oxygen use,
intensive care unit admission, mechanical ventilation and mortality,
with the primary endpoint a composite of any of these. Plasma
levels of inflammatory cytokines and chemokines were measured in
a subset. Results. Twenty-two of 168 (13.1%) in the cohort received
COX-2 inhibitors [median duration 3 days, interquartile range (IQR)
3–4.25]. Median age was 61 (IQR 55–67.75), 44.6% were female, and
72.6% had at least one comorbidity. A lower proportion of patients
receiving COX-2 inhibitors met the primary endpoint: 4 (18.2%)
versus 57 (39.0%), P = 0.062. This difference was less pronounced
after adjusting for baseline difference in age, gender and
comorbidities in a multivariate logistic regression model [adjusted
odds ratio (AOR) 0.45, 95% CI 0.14–1.46]. The level of interleukin-6
declined after treatment in five of six (83.3%) treatment group
patients [compared to 15 of 28 (53.6%) in the control group] with a
greater reduction in absolute IL-6 levels (P-value = 0.025).
Conclusion. Treatment with COX-2 inhibitors was not associated
with an increase in adverse outcomes. Its potential for therapeutic
use as an immune modulator warrants further evaluation in a large
randomised controlled trial.
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INTRODUCTION
The coronavirus disease 2019 (COVID-19)
pandemic has placed a significant strain on
healthcare systems, especially scarce intensive care
unit (ICU) resources. Up to five per cent of
patients develop critical illness requiring ICU care1
and demand outstripping ICU resource capacity
has contributed to significant increases in case
fatality rates in some settings.2 Treatments to
reduce the risk of progression to severe disease
are important to mitigate this pressure on
resource availability and reduce mortality. To
date, the only drug that has proven effective in a
Phase 3 randomised controlled trial is
remdesivir3,4; however, its intravenous
formulation limits its broader use in both
outpatient settings and inpatients with milder
disease at presentation. A broader range of
therapeutics, including an oral drug that can be
prescribed for ambulatory patients to reduce the
risk of progression to severe disease, is still
required to fill this gap in the COVID-19
armamentarium.
Severe COVID-19 is associated with a
dysregulated hyper-inflammatory immune
response, with previous studies finding elevated
levels of inflammatory cytokines and chemokines
in patients with severe disease.5,6 Interleukin-6
(IL-6) has been identified as a key cytokine in this
inflammatory cascade.7,8 This immunopatho-
genesis of COVID-19 suggests that immuno-
modulators may be beneficial as an adjunct or
alternative to antivirals.5
The use of non-steroidal anti-inflammatory drugs
(NSAIDs) in the treatment of COVID-19 has
generated controversy, with contradictory
recommendations from various regulatory
authorities.9 A rapid review by the WHO found no
evidence to establish the safety or efficacy of
NSAIDs for COVID-19.10 Furthermore, much of the
discussion has over-looked NSAIDs selective for the
inducible cyclooxygenase-2 (COX-2) enzyme.9 COX-2
inhibitors (such as etoricoxib or celecoxib) are one
of the few treatments available with RCT evidence
of mortality reduction in severe influenza.11
We hypothesised that COX-2 inhibitors are safe
in the treatment of COVID-19, and may be
associated with a reduction in adverse outcomes
in high-risk older patients with pneumonia,
primarily through attenuation of the hyper-
inflammatory immune response associated with
severe disease.
RESULTS
In all, 1588 patients were admitted during the
study period and were screened; 168 (10.6%)
patients met inclusion criteria and were included
in the analysis. The other patients were excluded
based on age < 50 years or the absence of
pneumonia on chest radiograph on admission. As
all patients with confirmed COVID-19 infection
were admitted in accordance with national policy
during this period, there was a large proportion
of young patients with limited upper respiratory
tract involvement who did not fulfil the inclusion
criteria. Twenty-two (13.1%) patients in the study
cohort received at least a single dose of
etoricoxib; 12 received 60 mg once daily, and ten
received 90 mg once daily. Median treatment
duration was 3 days [range 1–7, interquartile
range (IQR) 3–4.25], and median day of initiation
was day 10 of illness (range 1–19, IQR 6.75–12.25).
The detailed clinical course of all patients in the
treatment group, including timing and duration
of COX-2 inhibitor treatment, is illustrated in
Figure 1.
The treatment group was significantly younger
(median age 56 years, IQR 53.8–61) and had fewer
comorbidities (median number of comorbidities 1,
IQR 0–2; Charlson’s score 0, IQR 0–0.25) compared
with the control group (median age 62, IQR 55.8–
68.3; number of comorbidities 2, IQR 0.75–3;
Charlson’s score 0.5, IQR 0–1) (Table 1). However,
there were no statistically significant differences
in known laboratory biomarkers for severe
infection, including baseline neutrophil and
lymphocyte counts, C-reactive protein (CRP) and
lactate dehydrogenase (LDH).12 No patient in the
treatment group required invasive or non-invasive
ventilation or was in the ICU when they first
received COX-2 inhibitor treatment.
Apart from COX-2 inhibitor treatment, the use
of other co-administered treatments was
heterogenous in the study cohort. As there were
no proven effective therapies during the study
period, a variety of agents including lopinavir–
ritonavir, hydroxychloroquine and interferon-beta
were prescribed on an off-label basis by managing
physicians. Eighteen patients received remdesivir as
part of ongoing clinical trials during the study
period. There were no statistically significant
differences in the use of these other treatments
between the treatment and control groups.
There were no statistically significant
differences in the individual adverse outcomes
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(requirement for supplemental oxygen, ICU
admission, mechanical ventilation or mortality),
although the overall incidence of the composite
outcome was substantially lower in the COX-2
treatment group: 4 (18.2%) versus 57 (39%), P-
value = 0.062 (Table 1). No patient in the
treatment group developed adverse drug
reactions from COX-2 inhibitors, including
gastrointestinal, renal or cardiovascular
complications.
Multivariate logistic regression analysis to adjust
for baseline differences between treatment and
control groups did not find a statistically
significant difference in the composite adverse
outcome with COX-2 inhibitor treatment
(adjusted odds ratio [AOR] 0.45, 95% CI 0.14–
1.46). There were also no significant differences
associated with composite adverse outcome by
age, male gender or Charlson’s score, although
there was a significant association with
Figure 1. Clinical course in relation to timing and duration of COX-2 inhibitor treatment.
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hypertension (AOR 2.05, 95% CI 1.04–4.06)
(Table 2).
Plasma samples were analysed longitudinally
during admission for 34 patients, including six who
received COX-2 inhibitor treatment, and 28 who
did not. Among patients who received COX-2
inhibitor treatment, samples were first measured
prior to treatment in one patient, and up to 5 days
post-commencement of treatment in five patients.
Median day of illness of first timepoint was day 9.5
(IQR 6.5–14.0) in the treatment group and day 9
(IQR 5.25–14.5) in the control group (P-value =
Table 1. Baseline characteristics and adverse outcomes of patients with and without COX-2 inhibitor treatment
Variable COX-2 inhibitor treatment (n = 22) No COX-2 inhibitor treatment (n = 146) P-value
Demographics
Age, years 56 (53.8–61.0) 62 (55.8–68.3) 0.002
Male gender 11 (50.0%) 82 (56.2%) 0.649
Comorbidities
Diabetes mellitus 4 (18.2%) 46 (31.5%) 0.316
Hypertension 7 (31.8%) 74 (50.7%) 0.113
Ischaemic heart disease 1 (4.5%) 14 (9.6%) 0.696
Chronic lung disease 0 (0.0%) 4 (2.7%) 0.432
Smoking 1 (4.8%) 4 (2.8%) 0.651
Number of comorbidities 1 (0–2) 2 (0.75–3) 0.010
Charlson’s score 0 (0–0.25) 0.5 (0–1) 0.018
Baseline investigations
White blood count (9109 L1) 4.45 (3.40–6.10) 5.15 (4.10–6.60) 0.082
Neutrophil count (9109 L1) 3.04 (2.09–4.62) 3.23 (2.44–4.59) 0.513
Lymphocyte count (9109 L1) 0.94 (0.78–1.15) 1.12 (0.81–1.44) 0.100
C-reactive protein (mg L1) 16.2 (10.3–24.8) 28.2 (8.4–63.2, n = 143) 0.129
Lactate dehydrogenase (U L1) 524 (409.8–645) 509 (418.5–685) 0.994
Creatinine (lmol L1) 67.5 (53.3–84.3) 73.0 (59.0–87.0) 0.198
Co-administered treatments
Lopinavir–ritonavir 2 (9.1%) 37 (25.3%) 0.109
Hydroxychloroquine 0 (0.0%) 9 (6.2%) 0.608
Remdesivir 1 (4.5%) 17 (11.6%) 0.473
Interferon-beta 1 (4.5%) 13 (8.9%) 0.697
Adverse outcomes
Supplemental oxygen 4 (18.2%) 56 (38.4%) 0.093
ICU admission 2 (9.1%) 32 (21.9%) 0.254
Mechanical ventilation 0 (0.0%) 19 (13.0%) 0.139
Mortality 0 (0.0%) 8 (5.6%) 0.599
Composite adverse outcome 4 (18.2%) 57 (39.0%) 0.062
Continuous variables are reported as median (interquartile range). Categorical variables are reported as absolute number (percentage).
Bold text indicates P < 0.05.
CI, confidence interval; ICU, intensive care unit; NA, not applicable.
Table 2. Univariate and multivariate logistic regression analysis for factors associated with composite adverse outcome
Variable
Univariate logistic regression analysis Multivariate logistic regression analysis
Odds ratio (95% CI) P-value Adjusted odds ratio (95% CI) P-value
Age 1.04 (1.00–1.07) 0.032 1.02 (0.98–1.06) 0.321
Male gender 1.26 (0.67–2.39) 0.472 1.17 (0.59–2.31) 0.652
Hypertension 2.46 (1.29–4.69) 0.006 2.05 (1.04–4.06) 0.039
Charlson’s score 1.24 (0.95–1.63) 0.119 1.04 (0.77–1.39) 0.819
COX-2 inhibitor treatment 0.35 (0.11–1.08) 0.067 0.45 (0.14–1.46) 0.185
The Hosmer and Lemeshow test for multivariate model, P = 0.751.
Bold text indicates P < 0.05.
CI, confidence interval.
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0.821, Mann–Whitney U-test). Median day of illness
of last timepoint was day 14 (IQR 12.75–21.75) in
the treatment group and day 18 (IQR 12.0–25.0) in
the control group (P-value = 0.635, Mann–Whitney
U-test). Serial measurement of plasma samples
showed reduction in the level of a key pro-
inflammatory cytokine, interleukin-6 (IL-6), after
COX-2 inhibitor treatment in majority (five of six;
83.3%) of patients in the treatment group, with
median (IQR) IL-6 level of 18.86 (10.16–
30.86) pg mL1 at the first timepoint, and median
(IQR) IL-6 level of 0.06 (0.06–0.06) pg mL1 at the
last timepoint after treatment (median delta IL-6
level of 18.80 pg mL1) (Figure 2a). In contrast, a
reduction in IL-6 was observed in approximately
half (15 of 28, 53.6%) of patients in the control
group, with median (IQR) IL-6 level of 11.99 (0.06–
36.86) pg mL1 at the first timepoint, and median
(IQR) IL-6 level of 2.11 (0.06–15.10) pg mL1 at the
last timepoint (Figure 2b and c). Change in IL-6
level was significantly different comparing
treatment and control groups (P-value = 0.025,
Mann–Whitney U-test) (Figure 2c). Other
inflammatory cytokines and chemokines measured
did not show uniform changes among the six
patients after COX-2 inhibitor treatment, and their
median levels are shown in Table 3. Timing of
sample collection of IL-6 levels is depicted in
Figure 1.
DISCUSSION
In this population at increased risk of severe
COVID-19 (≥ 50 years old and with radiographic
pneumonia), there was no evidence that COX-2
inhibitor treatment was associated with an
increase in adverse outcomes, supporting the use
of short duration therapy in COVID-19 for
symptom relief and as an anti-pyretic. The finding
that patients in the treatment group had fewer
adverse outcomes including a non-significant
reduction in progression to supplemental oxygen,
invasive mechanical ventilation or death is
intriguing but must be interpreted with caution.
First, the group receiving COX-2 inhibitors was
younger and had fewer comorbidities—even if
there were no evident differences in laboratory
biomarkers for severe disease including neutrophil
and lymphocyte counts, CRP and LDH.
Unmeasured confounding may explain some of
the differences in outcome if it introduced
systematic bias into which patients received COX-2
inhibitors. Although there was no significant
difference in the proportion of diabetes mellitus
between intervention groups, we did not record
quantitative measures such as the degree control
of diabetic control. Patients in the treatment
group may have had less diabetic nephropathy or
fewer vascular complications and hence been
Figure 2. Longitudinal profile of plasma IL-6 levels in patients with and without COX-2 inhibitor treatment. Concentrations of 45 immune
mediators were quantified using a 45-plex microbead-based immunoassay. (a) Cytokine levels were measured in the plasma fractions of COVID-
19 pneumonia patients aged ≥ 50 who received etoricoxib treatment (n = 6) at multiple timepoints and showed reduction in IL-6 level in five of
six patients. (b) Serial plasma cytokine levels were also monitored in COVID-19 pneumonia patients aged ≥ 50 in the control group (n = 28)
during illness progression. (c) Plasma samples from the first and last timepoints were also analysed from COVID-19 pneumonia patients aged
≥ 50 in the control group (n = 28). IL-6 profiles were compared between treatment and control groups. Statistical analyses were performed using
the Mann–Whitney U-test (*P < 0.05). Patient samples that are not detectable are assigned the value of logarithm transformation of limit of
quantification (LOQ). Cytokine level for healthy controls (n = 13) is indicated by the blue dotted line.
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology, Inc.
2020 | Vol. 9 | e1159
Page 5
SWX Ong et al. Safety and use of COX-2 inhibitors in COVID-19
assessed by the managing physician as better able
to tolerate COX-2 inhibitors.
Second, this is a small retrospective study, which
limits the generalisability of our findings.
Although there were a large number of patients
with confirmed COVID-19 admitted during the
study period, only a small proportion (10.6%) met
the inclusion criteria and were including in the
data analysis. As a result of the small sample size,
it was only powered to detect large differences in
clinical outcomes. Smaller but clinically relevant
differences in outcomes would not be identified
as statistically significant.
Third, sample collection for IL-6 levels was not
done systematically before and after intervention,
as cytokine analysis was carried out as part of a
Table 3. Concentrations of immune mediators in subset of patients (n = 34)
No Immune mediator
No COX-2 inhibitor treatment (n = 28)
Median concentration, pg mL1
COX-2 inhibitor treatment (n = 6)
Median concentration, pg mL1
First timepoint Last timepoint Difference First timepoint Last timepoint Difference
1 BDNF 16.21 21.42 5.21 28.38 19.84 8.54
2 EGF 0.17 0.17 0.00 1.66 0.17 1.49
3 Eotaxin 17.74 14.77 2.97 9.55 10.53 0.98
4 FGF-2 0.18 0.18 0.00 0.18 0.18 0.00
5 GM-CSF 0.82 0.82 0.00 0.82 0.82 0.00
6 GRO-alpha 0.05 0.05 0.00 1.02 0.05 0.97
7 HGF 164.80 133.10 31.7 59.91 45.37 14.54
8 IFN-alpha 0.02 0.02 0.00 1.00 0.02 0.98
9 IFN-gamma 8.55 5.78 2.77 13.50 6.95 6.55
10 LIF 4.97 4.59 0.38 3.56 4.99 1.43
11 MCP-1 67.62 57.41 10.21 92.72 48.17 44.55
12 MIP-1 alpha 1.92 2.00 0.08 0.11 1.11 1.00
13 MIP-1 beta 39.16 41.12 1.96 34.49 41.33 6.84
14 PDGF-BB 20.03 35.01 14.98 20.23 59.75 39.52
15 PIGF-1 1.52 4.92 3.40 0.19 4.72 4.53
16 RANTES 29.71 36.56 6.85 24.08 45.76 21.68
17 SCF 4.32 4.43 0.11 3.91 3.67 0.24
18 SDF-1 alpha 598.10 665.70 67.6 510.90 667.00 156.10
19 IP-10 49.93 18.30 31.63 66.44 21.50 44.94
20 TNF-alpha 5.97 5.28 0.69 4.25 6.82 2.57
21 TNF-beta 2.98 2.98 0.00 2.98 2.98 0.00
22 VEGF-A 131.40 145.20 13.8 102.50 159.50 57.00
23 VEGF-D 0.10 0.10 0.00 4.42 4.68 0.26
24 bNGF 0.26 0.75 0.49 1.62 1.03 0.59
25 IL-1 alpha 0.01 0.01 0.00 0.01 0.67 0.66
26 IL-1 beta 1.71 1.98 0.27 1.36 2.34 0.98
27 IL-1RA 861.10 623.40 237.70 916.00 821.10 94.90
28 IL-2 13.87 13.50 0.37 11.62 9.72 1.90
29 IL-4 0.21 0.21 0.00 0.21 0.21 0.00
30 IL-5 0.04 0.04 0.00 0.04 0.04 0.00
31 IL-8 0.15 0.15 0.00 0.15 0.15 0.00
32 IL-9 2.35 2.35 0.00 2.35 2.35 0.00
33 IL-7 0.44 0.19 0.25 1.44 0.60 0.84
34 IL-10 0.04 0.04 0.00 0.04 0.04 0.00
35 IL-12p70 0.03 0.07 0.04 1.16 0.87 0.29
36 IL-13 0.20 0.20 0.00 0.20 0.20 0.00
37 IL-15 2.48 1.12 1.36 1.07 3.83 2.76
38 IL-17A 0.08 0.08 0.00 0.08 1.72 1.64
39 IL-18 80.14 47.03 33.11 52.58 32.82 19.76
40 IL-21 0.38 0.38 0.00 0.38 0.38 0.00
41 IL-22 0.36 0.36 0.00 0.36 0.36 0.00
42 IL-23 0.32 0.32 0.00 0.32 0.32 0.00
43 IL-27 0.99 0.99 0.00 0.99 8.50 7.51
44 IL-31 2.69 2.69 0.00 2.69 2.69 0.00
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separate observational study, and only
retrospectively correlated to COX-2 inhibitor
treatment in this study. Some patients (T2 and T7)
in the treatment group had IL-6 levels measured
only 4 days after initiation of COX-2 treatment,
and it is thus difficult to be sure that this
reduction in IL-6 can be attributable to COX-2
inhibitor treatment. With the small sample size for
IL-6 measurements in the treatment group, these
IL-6 data are primarily descriptive and exploratory,
and further study is required to establish a clear
correlation between COX-2 inhibitor treatment
and its impact on IL-6 levels in COVID-19.
Fourth, we did not assess the effect of co-
administered treatments including other antivirals
or immunomodulators. As the use of these other
agents was heterogenous in the study population,
we did not account for the interactions between
co-administered treatments and COX-2 inhibitor
treatment in the multivariate model.
Despite these limitations, the results indicate a
possible signal towards clinical benefit, which is
supported by a biologically plausible physiologic
mechanism and a detailed analysis of a subset of
six patients in the treatment group. This provides
an impetus for further analysis in a larger
prospective clinical trial.
The dysregulated immune response associated
with severe COVID-19 is well characterised, with
multiple studies showing elevated serum levels of
inflammatory cytokines in patients with severe
disease and mortality.5,6,13 Post-mortem studies
have confirmed that immune-mediated lung injury
underlies the pathogenesis of severe pneumonitis
seen in some patients.14 COVID-19 infection has
also been associated with endotheliitis because of
direct viral infection of endothelial cells and the
host inflammatory response.15
While only six patients in the treatment group
had measurements of serial plasma IL-6, a
reduction in IL-6 levels after treatment is
promising, given the association of elevated IL-6
with severe disease.5,8 We postulate that a
reduction in pro-inflammatory immune response
may be associated with reduced lung damage,
resulting in fewer adverse outcomes and reducing
risk of progression to severe disease.
The COX-2 enzyme has been shown to be
hyper-induced in the pro-inflammatory cascade in
influenza,16 and use of COX-2 inhibitors was
associated with reduction in IL-6 and IL-10 levels,
incidence of ventilator-associated pneumonia and
mortality in a randomised controlled trial.11,17 Its
use in influenza is further supported by in vitro
and murine models.18,19 COX-2 inhibitor
treatment has also been shown to reduce IL-6
levels in other non-infective inflammatory diseases
such as inflammatory arthritis and
pancreatitis.20,21 These provide a biologic basis for
its potential efficacy in other respiratory viruses
whereby pathophysiology is driven by similar
inflammatory states, such as in COVID-19.
In conclusion, COX-2 inhibitors are an attractive
intervention in COVID-19 for relief of symptoms and
fever given their low cost, wide availability and
potential for beneficial immune modulation. We
did not find that COX-2 inhibitors increased the risk
of severe COVID-19 in a population of older adults
with pneumonia, but found evidence of beneficial
reduction in inflammatory cytokines. The trend to a
reduction in adverse outcomes with COX-2
inhibitors provides the rationale for an adequately
powered randomised controlled trial to further
elaborate on safety and to examine whether they
may attenuate disease severity in COVID-19.
METHODS
Clinical data
We conducted a retrospective cohort study of all patients
with COVID-19 infection confirmed by SARS-CoV-2
polymerase chain reaction assay and admitted to the
National Centre for Infectious Diseases, Singapore, from 22
January to 4 April 2020. Inclusion criteria were age
≥ 50 years old and pneumonia diagnosed on chest
radiography. As need for supplemental oxygen therapy was
part of the primary endpoint, requiring supplemental
oxygen on admission was an exclusion criterion.
Clinical data were collected by study investigators from
medical records. Informed consent for data collection was
waived as part of an outbreak investigation authorised by
the Ministry of Health, Singapore, under the Infectious
Diseases Act. Adverse outcomes analysed were hypoxia
requiring supplemental oxygen (oxygen saturation < 94%
on room air), ICU admission, mechanical ventilation and
mortality. The primary endpoint was a composite of these
(having any of these adverse outcomes). Data were
collected up until discharge or death.
Immunological profiling
Independently from the retrospective study, clinical data
and serial blood samples were collected from a subgroup of
hospitalised individuals with PCR confirmed COVID-19 who
participated in the observational PROTECT study. This
COVID-19 characterisation protocol was approved by the
National Healthcare Group Domain Specific Review Board,
Study Reference 2012/00917. Written informed consent was
obtained from all study participants for sample collection.
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology, Inc.
2020 | Vol. 9 | e1159
Page 7
SWX Ong et al. Safety and use of COX-2 inhibitors in COVID-19
These patients formed a subset of the above group of
patients identified after application of the inclusion criteria,
and were identified by cross-checking the list of included
patients with the PROTECT study database.
Plasma samples were tested for cytokine levels to assess
evolution of the inflammatory response. Briefly, serial
plasma samples were tested for immune mediator levels
using Cytokine/Chemokine/Growth Factor 45-Plex Human
ProcartaPlexTM Panel 1 (Thermo Fisher Scientific, Waltham,
MA, USA). Samples were treated by solvent/detergent
treatment based on TritonTM X-100 (1%) for virus
inactivation.22 Standards and plasma from COVID-19
patients and healthy controls were incubated with
fluorescent-coded magnetic beads pre-coated with
respective capture antibodies in a 96 black clear-bottom
plate. After washing, biotinylated detection antibodies
were incubated with the cytokine-bound beads for 1 h.
Finally, streptavidin-PE was added and incubated for
another 30 min. Measurements were acquired on the
FLEXMAP 3D (Luminex Corporation, Austin, TX, USA) using
xPONENT 4.0 (Luminex) acquisition software. Data analysis
was done on Bio-Plex ManagerTM 6.1.1 (Bio-Rad
Laboratories, Hercules, CA, USA). Standard curves were
generated with a 5-PL (5-parameter logistic) algorithm,
reporting values for both MFI and concentration data.
Statistical analysis
Categorical variables were compared using the Chi-square or
Fisher’s exact tests as appropriate, and continuous variables
were compared using the Mann–Whitney U-test. P-
value < 0.05 was considered significant. A multivariable
logistic regression model was constructed to evaluate factors
associated with the composite adverse outcome. All analyses
were performed using SPSS version 26 (IBM Corp, Armonk,
NY, USA). No pre-determined sample size calculation was
performed as this was a retrospective cohort study.
Internal control samples were included in each Luminex
assay to remove any potential plate effects. Readouts of
these samples were then used to normalise the assayed
plates. A correction factor was obtained from the
differences observed across the multiple assays, and this
correction factor was then used to normalise all the
samples. The concentrations were logarithmically
transformed to ensure normality. Samples with
concentration out of measurement range were assigned the
value of logarithmic transformation of Limit of
Quantification (LOQ). Plots were generated using GraphPad
Prism version 8 (GraphPad Software, San Diego, CA, USA).
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